Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics N.V. (Nasdaq: PRQR) generates a steady flow of news as a clinical-stage biopharmaceutical company advancing RNA editing therapies. Its updates center on the Axiomer RNA base editing platform and a pipeline of editing oligonucleotides designed to correct or modulate disease-related targets at the RNA level. News coverage on this page reflects company announcements, clinical milestones, financial updates, and scientific presentations related to its programs in liver, CNS, and other genetically defined diseases.
Investors and followers of PRQR can expect news about the progress of AX-0810, ProQR’s lead investigational RNA editing oligonucleotide targeting NTCP for cholestatic diseases. Recent releases describe the submission and authorization of a Clinical Trial Application, the initiation of a Phase 1 first-in-human study in healthy volunteers in the Netherlands, and early safety and pharmacokinetic observations from the first cohort. Updates also outline plans for target engagement readouts and the future inclusion of a patient cohort in the same trial.
News items also highlight earlier-stage pipeline programs such as AX-2402 for Rett syndrome (MECP2 R270X), AX-2911 for metabolic liver disease including MASH (PNPLA3 I148M), and AX-1412 for cardiovascular disease (B4GALT1). ProQR reports non-clinical proof-of-concept data, development candidate selections, and functional results in disease-relevant models. Financial press releases provide quarterly operating and financial results, cash and cash equivalents, collaboration revenue from Eli Lilly, and comments on cash runway.
Additional PRQR news covers participation in scientific and investor conferences, including ASGCT, the RNA Editing Summit, OTS, TIDES USA, and healthcare investor events. These communications feature presentations on ADAR-mediated RNA editing of NTCP, PNPLA3, and MECP2, as well as platform-focused talks on optimizing editing oligonucleotides for therapeutic use. Bookmark this page to follow ProQR’s disclosed clinical data, pipeline milestones, collaboration developments, and financial reporting as they are released through press announcements and SEC-furnished materials.
ProQR Therapeutics reported its Q2 2021 financial results, highlighting significant progress in its clinical trials and partnerships. The Illuminate trial of sepofarsen for LCA10 is set to release top-line data in H1 2022. The QR-421a trials for Usher syndrome and retinitis pigmentosa aim to start by year-end 2021, while initial data from the QR-1123 trial is expected in Q4 2021. Financially, ProQR had €139.4 million in cash as of June 30, 2021, with a net loss of €15.8 million for the quarter. New partnerships and a public offering bolstered its financial position.
ProQR Therapeutics (Nasdaq: PRQR) announced its management will present during a fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, from 3:00 to 3:25 pm EDT. The presentation will be available via a live webcast on ProQR's website under the Investors & Media section, with an archived version accessible for 30 days post-event. ProQR focuses on transformative RNA therapies for genetic eye diseases such as Leber congenital amaurosis 10 and Usher syndrome, utilizing proprietary RNA repair technologies.
ProQR Therapeutics reported significant progress in Q1 2021, completing enrollment for the pivotal Illuminate trial of sepofarsen for LCA10. Positive Phase 1/2 data for QR-421a was shared, with plans for two pivotal Phase 2/3 trials by year-end. The company secured $103.5 million from a public offering, bolstering its balance sheet for further clinical developments. Q1 2021 net loss was €12.6 million, improving from €16.1 million year-over-year. Upcoming milestones include top-line results from Illuminate anticipated in H1 2022.
Yarrow Biotechnology, formed by RTW Investments, has licensed ProQR Therapeutics' antisense oligonucleotide (ASO) technology for non-ophthalmology applications. ProQR stands to gain up to $115 million in upfront and milestone payments, alongside royalties on future sales. ProQR will also receive an undisclosed equity stake in Yarrow. The partnership aims to develop ASO-based therapies targeting disorders with significant unmet needs. Roderick Wong from RTW believes in the transformative potential of RNA-based therapies in genetically-defined diseases.
ProQR Therapeutics N.V. (Nasdaq:PRQR) announced a virtual presentation at ARVO on May 6, 2021, detailing data from its Phase 1/2 InSight trial of sepofarsen, aimed at treating Leber Congenital Amaurosis type 10 (LCA10). This presentation follows earlier discussions from July 2020, with new data expected in H2 2021. Currently, there are no approved treatments for LCA10, affecting around 2,000 individuals in the Western world. Sepofarsen is a pioneering RNA therapy addressing the underlying genetic cause, with significant designations from regulatory bodies.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced its participation in the Kempen Life Sciences Conference 2021 on April 28, 2021, hosting 1x1 meetings. The company focuses on developing transformative RNA therapies for inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome, and retinitis pigmentosa. ProQR utilizes proprietary RNA repair platform technologies to advance its pipeline, emphasizing patient-centered approaches.
ProQR Therapeutics N.V. (Nasdaq: PRQR) will hold its Annual General Meeting of Shareholders on May 19, 2021, at 16:00 CET via videoconference. Relevant documents, including the meeting agenda, will be available in the 'Investors & Media' section of their website. ProQR is focused on developing transformative RNA therapies for inherited retinal diseases, aiming to improve the lives of patients with conditions like Leber congenital amaurosis and retinitis pigmentosa.
ProQR Therapeutics (Nasdaq:PRQR) announced positive findings in the scientific journal Nature Medicine regarding its RNA therapy, sepofarsen, for treating Leber Congenital Amaurosis 10 (LCA10). The case report highlights significant visual improvements in a patient treated with sepofarsen, indicating potential for early-stage disease management. This therapy is designed to correct the underlying genetic mutation and has received various designations from regulatory authorities, reflecting its promise in treating this severe condition.
ProQR Therapeutics N.V. (Nasdaq: PRQR) successfully closed an underwritten public offering of 13,846,154 ordinary shares at a price of $6.50 per share, raising approximately $103.5 million in gross proceeds. The offering included the full exercise of the underwriters' option for an additional 2,076,923 shares. Citigroup and Evercore ISI led the offering, with other banks participating as joint managers. The shares are registered under an effective shelf registration statement filed with the SEC. ProQR focuses on developing transformative RNA therapies for inherited retinal diseases.
ProQR Therapeutics N.V. (Nasdaq:PRQR) will present a virtual paper on April 10, 2021, at the AAPOS annual meeting. The presentation focuses on the innovative genetic therapy using antisense oligonucleotide treatment for Leber Congenital Amaurosis 10 (LCA10), specifically targeting the prevalent p.Cys998X mutation in the CEP290 gene. This condition leads to significant vision loss in children, and there are currently no approved treatments. ProQR's investigational RNA therapy, Sepofarsen, aims to address this gap and has received multiple designations from regulatory authorities.